Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

J Clin OncolJun 1, 2026 (epub)
Clinical ResearchOncology (Medical)

Adnan Khattak, Matteo S Carlino, Tarek Meniawy et al.

✦ AI-curated · Sources linked

In 30 seconds

The phase IIb KEYNOTE-942 study evaluated the efficacy of intismeran autogene plus pembrolizumab compared to pembrolizumab alone in patients with resected stage IIIB to IV melanoma. After five years, the combination therapy significantly improved recurrence-free survival (RFS) with a hazard ratio of 0.510 and distant metastasis-free survival (DMFS) with a hazard ratio of 0.411, indicating sustained treatment benefits.

Key findings

  • Intismeran plus pembrolizumab improved RFS with a hazard ratio of 0.510.
  • DMFS was also significantly improved with a hazard ratio of 0.411.
  • A favorable trend in overall survival was observed with a hazard ratio of 0.471.
  • The safety profile remained manageable with no new safety signals.

Why it matters

These findings suggest that combining intismeran with pembrolizumab may offer enhanced long-term outcomes for patients with high-risk resected melanoma, potentially influencing treatment strategies in this population.

Source

PubMed · PMID 42223134

Published in J Clin Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.